Speragen is developing an enzyme replacement therapy (ERT) for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) by utilizing intact SSADH proteins delivered to mitochondria, addressing the lack of effective treatments for this rare genetic disorder. The company also implements a newborn screening program to facilitate early diagnosis, improving patient outcomes through timely intervention.
Funding
Funding not disclosed
Founders
Product
Problem
Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) lacks effective treatments, leaving patients with neurological and neuromuscular problems, including intellectual disability, developmental delay, and seizures. Current management focuses on symptomatic relief, highlighting the urgent need for targeted therapies.
Solution
Speragen is developing an enzyme replacement therapy (ERT) designed to address the underlying cause of SSADHD by delivering functional SSADH proteins directly to the mitochondria. This approach aims to restore proper metabolic function and alleviate the symptoms associated with the deficiency. In conjunction with GC Pharma, Speragen is working towards preclinical studies and clinical trials to evaluate the safety and efficacy of the ERT. Additionally, Speragen is implementing a newborn screening program to enable early diagnosis and intervention for affected individuals.
Target Audience
The primary target audience includes individuals diagnosed with SSADHD, their families, and healthcare providers specializing in rare genetic disorders.
Features
- Enzyme replacement therapy (ERT) using intact SSADH proteins
- Targeted delivery of functional SSADH proteins to mitochondria
- Newborn screening program for early SSADHD diagnosis
- Collaboration with GC Pharma for manufacturing, clinical trials, and regulatory approval
- Patent-protected SSADH protein encoding plasmid